We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+37.96%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
+$239M
Cap. Flow
+$117M
Cap. Flow %
10.4%
Top 10 Hldgs %
67.61%
Holding
75
New
17
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$58.1M
2
YMAB
Y-mAbs Therapeutics
YMAB
+$53.5M
3
SNY icon
Sanofi
SNY
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$13.3M
5
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
+$12.4M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$14.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$9.46M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$8.96M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.8M
5
BLUE
bluebird bio
BLUE
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 85.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$7.79M 0.69%
698,225
+441,533
+172% +$5.08M
AZN icon
27
CALL
AstraZeneca
AZN
$263B
$7.65M 0.68%
+96,700
New +$7.31M
EXEL icon
28
Exelixis
EXEL
$13.9B
$7.15M 0.64%
+403,594
New +$7.87M
ANAB icon
29
AnaptysBio
ANAB
$1.6B
$6.95M 0.62%
+69,615
New +$5.78M
ADMS
30
DELISTED
Adamas Pharmaceuticals
ADMS
$6.92M 0.62%
345,756
+62,358
+22% +$1.46M
AIMT
31
DELISTED
Aimmune Therapeutics
AIMT
$6.06M 0.54%
222,295
-152,749
-41% -$4.32M
CHMA
32
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.87M 0.52%
1,767,102
– –
CPRX
33
DELISTED
Catalyst Pharmaceutical
CPRX
$5.86M 0.52%
1,549,552
+99,595
+7% +$312K
DERM
34
DELISTED
Dermira, Inc.
DERM
$5.4M 0.48%
495,293
+130,953
+36% +$1.32M
FOLD
35
DELISTED
Amicus Therapeutics
FOLD
$5.39M 0.48%
+445,969
New +$6.24M
KDMN
36
DELISTED
Kadmon Holdings, Inc.
KDMN
$5.15M 0.46%
1,842,502
+72,919
+4% +$259K
BHVN
37
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5M 0.45%
+133,066
New +$4.89M
SRPT icon
38
Sarepta Therapeutics
SRPT
$1.66B
$4.83M 0.43%
29,915
-18,485
-38% -$2.53M
RYTM icon
39
Rhythm Pharmaceuticals
RYTM
$7B
$4.65M 0.41%
159,302
+19,002
+14% +$600K
KURA icon
40
Kura Oncology
KURA
$922M
$4.33M 0.39%
247,385
+79,485
+47% +$1.52M
BPMC
41
DELISTED
Blueprint Medicines
BPMC
$4.01M 0.36%
51,339
-40,861
-44% -$2.84M
FOMX
42
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.83M 0.34%
668,619
-13,780
-2% -$78.8K
CLSD
43
DELISTED
Clearside Biomedical
CLSD
$3.73M 0.33%
40,461
+11,601
+40% +$1.38M
HSTO
44
DELISTED
Histogen Inc. Common Stock
HSTO
$3.13M 0.28%
2,695
-1,599
-37% -$1.47M
EPZM
45
DELISTED
Epizyme, Inc
EPZM
$3.09M 0.28%
+291,318
New +$3.33M
OTIC
46
DELISTED
Otonomy, Inc.
OTIC
$2.72M 0.24%
987,778
+7,800
+0.8% +$25K
PDSB icon
47
PDS Biotechnology
PDSB
$38.1M
$2.34M 0.21%
142,636
– –
FSTX
48
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.29M 0.2%
+47,412
New +$2.37M
ARQL
49
DELISTED
Arqule Inc
ARQL
$2.19M 0.2%
+386,271
New +$2.2M
FATE icon
50
Fate Therapeutics
FATE
$281M
$1.71M 0.15%
+104,891
New +$1.24M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2018 Portfolio in Review

As of Q3 2018, Sofinnova Investments held 75 positions worth $1.12B, up 27% from $883M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $117M of net new capital in Q3 2018, opening 17 new positions and adding to 14 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $9.46M trimmed.

  • Sofinnova Investments's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,059,146 shares worth $59.6M.
  • Sofinnova Investments added most to Puma Biotechnology in Q3 2018, an estimated $13.3M increase.
  • Sofinnova Investments's biggest Q3 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $9.46M.
  • Sofinnova Investments fully exited Celgene Corp in Q3 2018, selling an estimated $14.6M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.12B portfolio in Q3 2018.
  • Sofinnova Investments opened 17 new positions and closed 14 in Q3 2018.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $1.12B.

Based on Sofinnova Investments's 13F filing for Q3 2018, filed 15 Nov 2018.